内外资机构共识：2026年中国股市将延续涨势 2025年末的11连阳为2026年开局积攒了饱满的市场情绪，而过去一年市场出现的诸多积极变化，如AI 的创新突破、"反内卷"政策不断推进，以及企业盈利的改善，都为2026年中国股市的进一步上涨奠定了 坚实基础。展望2026年，看多中国资产，特别是看多中国的科技资产正成为内外资机构的一致共识。站 在开年时点，人心思涨的环境下市场震荡向上的概率更高。亚洲新兴市场板块中，摩根大通、花旗私人 银行维持对中国市场的超配评级。高盛研究团队则预测，中国股票市场到2027年末有望实现38%的涨 幅。这一涨幅的主要驱动力为企业盈利增长，高盛认为中国企业盈利2026年及2027年将分别增长14%和 12%。（上海证券报） 万亿养老金迎来长周期考核 据证券时报消息，万亿年金基金将进入长周期考核阶段，相关指导意见已出台并正在推进。这一举措旨 在促进年金基金的长期投资，改变短期化考核的倾向。年金基金作为养老保障体系的"第二支柱"，其投 资运营规模已超过7.7万亿元。通过延长合同期限和考核周期，优化中长期考核机制，年金基金将更注 重长期风险控制和跨周期资产配置，以提升其稳健性和收益能力。此举 ...

Core Insights - Lexaria Bioscience Corp. has released additional data from its Phase 1b clinical study GLP-1-H24-4, which focuses on the efficacy of its DehydraTECH™ technology compared to Rybelsus® [1][2] Secondary Efficacy Parameters - At week 16, the DHT arms showed no statistically significant differences compared to the Rybelsus® control in mean fasting glucose, cholesterol, and LDL cholesterol [3] Body Composition - The DHT-semaglutide arm showed a modest reduction in fat mass of -1.08 kg and total mass of -1.40 kg, while the Rybelsus® control arm achieved greater reductions of -3.55 kg in fat mass and -5.36 kg in total mass, with a higher reduction in lean mass of -1.72 kg [4] Blood Pressure Analyses - The DHT-CBD arm achieved significant reductions in blood pressure, with a mean change of -4.6 mmHg in systolic and -4.0 mmHg in diastolic blood pressure at week 4 [5][6] Pharmacokinetic Exploratory Analyses - Plasma CBD concentrations were quantifiable through week 16 in the DHT-CBD arms, while semaglutide concentrations were not quantifiable due to assay issues, although preliminary tests indicated measurable levels [8] Health Survey Results - Participants in the DHT-semaglutide arm reported mean improvements of over 5 points in physical components and over 3 points in mental components of the SF-36 health survey, compared to modest improvements in the Rybelsus® control arm [9][10] Overall Conclusions and Next Steps - The study met its primary endpoint, demonstrating good safety and tolerability of all DHT test articles, with positive findings across various parameters compared to Rybelsus® [11] Future Plans - Lexaria plans to pursue further clinical testing with a DHT + SNAC + semaglutide composition and is in discussions with a pharmaceutical company regarding the dataset from the study [15][17][18]

Core Insights - Lexaria Bioscience Corp. has successfully achieved its primary endpoint in the Phase 1b study GLP-1-H24-4, demonstrating significant efficacy in reducing unwanted side effects compared to Rybelsus® [2][13] - The company raised a total of $7.5 million through financing activities, which will support new development opportunities throughout 2026 [2][18] - The study results indicate that DehydraTECH-semaglutide reduced overall side effects by 48% and gastrointestinal side effects by 55% compared to Rybelsus® [4][6] Study Results - All four DehydraTECH (DHT) test articles were found to be safe and well-tolerated, meeting the primary endpoint objective [3][13] - The total adverse events (AEs) for DHT-semaglutide were reduced by 47.9% compared to Rybelsus®, with a statistically significant reduction in gastrointestinal AEs [6][10] - The study included 126 participants, focusing on safety and tolerability, with DHT-semaglutide showing the best performance among the tested formulations [19] Efficacy Assessments - The primary efficacy endpoint of HbA1c reduction showed comparable performance between DHT-semaglutide and Rybelsus®, with no statistically significant difference [10][11] - Bodyweight reduction was more pronounced in the Rybelsus® control arm compared to all DHT arms, raising questions about the differing results [11][12] - The study's findings suggest that even small reductions in HbA1c can improve cardiovascular outcomes in overweight or obese individuals [10] Future Directions - Lexaria plans to investigate the DHT-semaglutide formulation further, potentially incorporating salcaprozate sodium (SNAC) in future studies [14][15] - The company aims to relay the study dataset to its pharmaceutical partner under a Material Transfer Agreement, which has been extended to April 30, 2026 [16][17] - Additional non-primary endpoint results are expected to be released soon, providing further insights into the study's findings [20]

Financial Performance & Strategic Aspirations - For the first nine months of 2025, Novo Nordisk reported sales growth of 15% at Constant Exchange Rates (CER)[11] - Operating profit growth was 10% at CER, impacted by restructuring costs of 9 billion DKK[11, 68] - The company anticipates annualised savings of approximately 8 billion DKK for reinvestment in future growth[17] - Novo Nordisk is transforming with aim to meet future patient needs and allow for investment in growth opportunities[16] Market & Therapeutic Focus - Obesity care sales reached 59.9 billion DKK, reflecting a 41% increase at CER[11] - Rare disease sales amounted to 14.3 billion DKK, a 13% increase at CER[11] - Diabetes value market share stood at 31.6%, a decrease of 2.3 percentage points[11] - The company aims to strengthen its diabetes leadership, targeting a global value market share exceeding one-third[72] Pipeline & Innovation - Novo Nordisk is progressing its pipeline, including US approval for Rybelsus® CV indication and Wegovy® MASH indication[11] - The company agreed to acquire Akero, including a phase 3 MASH asset, and proposed the acquisition of Metsera, Inc for up to 10 billion USD[11, 47] - Cagrilintide 2.4 mg will be investigated in RENEW phase 3 programme with potential to be the first amylin on the market[58]

Core Viewpoint - The FDA has approved Rybelsus® as the only oral GLP-1 medication for reducing the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes, regardless of prior cardiovascular events, highlighting the need for treatment options beyond blood sugar control [2][3][5]. Group 1: FDA Approval and Clinical Evidence - Rybelsus® is now recognized as the only oral GLP-1 drug approved for both primary and secondary prevention of MACE in high-risk type 2 diabetes patients [5]. - The SOUL study aimed to evaluate the effectiveness of oral semaglutide 14mg combined with standard treatment in reducing MACE risk, with MACE defined as cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke [5][6]. - In the study, 12.0% of patients receiving semaglutide experienced MACE events compared to 13.8% in the placebo group, demonstrating a hazard ratio of 0.86, indicating a 14% relative risk reduction over four years [6]. Group 2: Safety and Side Effects - The overall safety profile of oral semaglutide 14mg was consistent with previous studies, with serious adverse events (SAEs) occurring in 47.9% of the semaglutide group compared to 50.3% in the placebo group [8]. - The most common SAEs included heart disease and infections, with gastrointestinal issues being slightly more prevalent in the semaglutide group (5.0% vs. 4.4%) [8]. - Discontinuation due to adverse events occurred in 15.5% of the semaglutide group versus 11.6% in the placebo group, primarily due to gastrointestinal disorders and infections [8]. Group 3: Future Developments - The company has submitted a supplemental application to the FDA for a daily oral semaglutide formulation, Wegovy®, aimed at treating obesity, with results expected later this year [9].

Core Insights - The study conducted by Lexaria Bioscience Corp. indicates that the DehydraTECH processing of semaglutide enhances its brain biodistribution compared to conventional formulations, potentially improving safety and efficacy [1][3][6] Study Findings - The primary objective of the study was to assess whether DehydraTECH processing significantly improves the biodistribution of semaglutide [2] - The DehydraTECH-FTS composition showed a higher apparent trend in brain biodistribution across all tested doses, with the 5mg DehydraTECH-FTS achieving greater brain semaglutide fluorescent signal intensity than the 15mg Rybelsus® equivalent [3][5] - Fluorescent imaging revealed that all three DehydraTECH doses tested had higher fluorescence in key brain regions compared to naïve and vehicle groups, while only the highest dosage of Rybelsus® surpassed these groups [5] Mechanism and Implications - The study suggests that enhanced brain biodistribution may be linked to the pharmacodynamic performance of GLP-1 drugs, which are known to interact with brain neurochemistry [6][7] - Semaglutide's ability to regulate body weight through GLP-1 receptor activation in the brain could lead to appetite suppression without common side effects like nausea [6] - Lexaria's findings may support the development of safer and more effective GLP-1 drugs in the future [8] Research Methodology - The preclinical pilot study involved Sprague Dawley rats and utilized non-invasive whole-body imaging and ex vivo organ analysis to evaluate the biodistribution of oral semaglutide [9][12] - A total of 25 male rats were used, with 22 allocated for dosing and 3 as untreated controls, examining both DehydraTECH and Rybelsus® equivalent compositions [12][13] Technology Overview - DehydraTECH is a patented drug delivery platform that enhances the absorption and effectiveness of various drugs, including those that cross the blood-brain barrier [14]

Core Insights - Novo Nordisk is set to present 35 abstracts related to its diabetes and obesity portfolio at the EASD congress 2025, highlighting the health benefits and weight loss effects of semaglutide, along with new obesity pipeline therapies [1][3][4] Company Developments - The company will host an R&D investor event on 17 September to discuss the science and abstracts presented at the congress, which will be available via live webcast [2] - Semaglutide is recognized for having the broadest approved indications for obesity and type 2 diabetes, contributing to weight loss and cardiovascular protection [3] Research Presentations - Key presentations include the SOUL trial on oral semaglutide's cardiovascular outcomes, and various studies on the effectiveness of semaglutide and its impact on eating behaviors and body composition [5][7][8] - The REDEFINE trials will present data on the efficacy of cagrilintide and amycretin as next-generation obesity treatments [11][17] Product Information - Semaglutide is marketed under the brand names Wegovy® (2.4 mg injection), Ozempic® (1.0 mg injection), and Rybelsus® (14 mg oral) [14] - The drug has a well-established safety profile supported by over 33 million patient-years of exposure since its launch in 2018 [13]

Core Insights - Novo Nordisk announced new data on the cardiovascular protective benefits of Wegovy® and Ozempic® to be presented at the ESC Congress 2025, highlighting the role of inflammation in atherosclerotic cardiovascular disease (ASCVD) [1][3] Group 1: Cardiovascular Benefits - Semaglutide has been shown to reduce the risk of cardiovascular events by 20-26%, leading to fewer hospitalizations, heart attacks, strokes, and deaths for individuals with diabetes and obesity [2] - The unique benefits of semaglutide on heart and kidney disease will be substantiated through both clinical trials and real-world evidence at the ESC Congress [4] Group 2: Scientific Presentations - Key presentations will include data on Ozempic® (1.0 mg), Rybelsus® (oral semaglutide), and Wegovy® (2.4 mg), focusing on their impact on conditions like atrial fibrillation and cardiometabolic benefits in type 2 diabetes [5][6] - Specific sessions will address the effects of semaglutide on heart failure outcomes, cardiovascular risk factors, and the relationship between inflammation and cardiovascular events [6][13] Group 3: Research and Evidence - Real-world evidence will be presented to analyze the impact of inflammation on mortality and major cardiovascular events in individuals with ASCVD [3][5] - The role of systemic inflammation in cardiovascular disease and chronic kidney disease will be explored through various studies and analyses during the congress [13][19]

Core Insights - Lexaria Bioscience Corp. has successfully completed a human study comparing oral DehydraTECH-liraglutide to injected Saxenda®-branded liraglutide, with partial results now available [1][8] - The study demonstrated a 22.7% reduction in adverse events (AEs) for oral DehydraTECH-liraglutide compared to Saxenda®, with significant reductions in nausea (67%) and gastrointestinal AEs (31%) [3][4] - Lexaria is seeking a pharmaceutical partner to develop an FDA-registered oral alternative to current injectable GLP-1 drugs, addressing an unmet market need [2][10] Study Details - The study involved 10 overweight volunteers, comparing daily doses of Saxenda® (0.6 mg) and DehydraTECH-liraglutide (45 mg) over a 7-day period [13] - The primary endpoint was the evaluation of safety and tolerability, with secondary objectives including pharmacokinetics and effects on body weight, blood glucose, and insulin levels [16] - Weight loss was observed in 9 out of 10 participants in both study arms, although it was not the primary goal of the study [5] Technology and Market Context - DehydraTECH is a patented drug delivery technology that enhances bio-absorption and reduces side effects, with 48 patents granted and more pending [17] - The study's results suggest that DehydraTECH-liraglutide could provide a viable oral alternative to Saxenda® and other injectable liraglutide products, which generated significant revenue for Novo Nordisk [12] - Lexaria's approach may allow for an expedited FDA regulatory pathway under the 505(b)(2) application, contingent on demonstrating comparable performance to existing injectable versions [6][10]